| scholarly article | Q13442814 |
| P2093 | author name string | Andrew J Wilson | |
| Dineo Khabele | |||
| Marta A Crispens | |||
| Jeanette Saskowski | |||
| Toby Barrack | |||
| Alexandra Steck | |||
| Kofi Sarfo-Kantanka | |||
| P2860 | cites work | Poly (ADP-ribose) polymerase inhibitors: recent advances and future development. | Q35895214 |
| Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers. | Q35897417 | ||
| BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group | Q36145443 | ||
| Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer | Q36521908 | ||
| Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control | Q36639688 | ||
| Evaluating cell lines as tumour models by comparison of genomic profiles | Q37025950 | ||
| Profile of panobinostat and its potential for treatment in solid tumors: an update | Q37324186 | ||
| Synthetic lethality between CCNE1 amplification and loss of BRCA1. | Q37353157 | ||
| Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System | Q37611723 | ||
| Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes | Q38616807 | ||
| Resistance to CDK2 inhibitors is associated with selection of polyploid cells in CCNE1-amplified ovarian cancer | Q39100297 | ||
| Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval | Q39712677 | ||
| Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation | Q40177923 | ||
| Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells | Q42081115 | ||
| The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects. | Q42699806 | ||
| Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen | Q42818142 | ||
| Whole-genome characterization of chemoresistant ovarian cancer. | Q50272478 | ||
| Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation | Q56240758 | ||
| Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer | Q56807699 | ||
| XRCC3 promotes homology-directed repair of DNA damage in mammalian cells | Q24597771 | ||
| Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers | Q27851474 | ||
| Integrated genomic analyses of ovarian carcinoma | Q27860518 | ||
| Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma | Q28534761 | ||
| Cancer statistics, 2016 | Q29547383 | ||
| Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors | Q29547463 | ||
| Hallmarks of 'BRCAness' in sporadic cancers | Q29618825 | ||
| Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial | Q29619615 | ||
| Residual gammaH2AX foci as an indication of lethal DNA lesions | Q33522060 | ||
| DNA fingerprinting of the NCI-60 cell line panel | Q33608214 | ||
| The therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancer | Q33659166 | ||
| Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer | Q33754744 | ||
| Hdac3 Is Essential for the Maintenance of Chromatin Structure and Genome Stability | Q34417264 | ||
| Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer | Q35141937 | ||
| Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS. | Q35176113 | ||
| Double-strand break repair by interchromosomal recombination: suppression of chromosomal translocations | Q35212139 | ||
| Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts | Q35448716 | ||
| Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy. | Q35542762 | ||
| The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells | Q35556954 | ||
| Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer | Q35631181 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ovarian cancer | Q172341 |
| P304 | page(s) | 143-151 | |
| P577 | publication date | 2016-07-19 | |
| P1433 | published in | Gynecologic Oncology | Q5625182 |
| P1476 | title | Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib | |
| P478 | volume | 143 |
| Q89649803 | CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes |
| Q97692537 | Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models |
| Q49340516 | Fanconi Anemia Signaling and Cancer |
| Q91995960 | Interferon-γ signaling is associated with BRCA1 loss-of-function mutations in high grade serous ovarian cancer |
| Q52642120 | The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer. |
| Q97524894 | Understanding the Mechanisms by Which Epigenetic Modifiers Avert Therapy Resistance in Cancer |
Search more.